Chenlight Biosciences: It is expected that the net profit in the first quarter of 2026 will decrease by 17.79% to increase by 5.04% year-on-year.

Sina Finance reported on March 30th that Morningstar Bio announced that the net profit for the first quarter of 2026 is expected to be between 90 million and 115 million yuan, a year-on-year decrease of 17.79% to an increase of 5.04%. During the reporting period, the company's business developed steadily, fully utilizing the inventory purchased in the previous year, actively adjusting its sales strategy, and temporarily controlling the market; the Zambian subsidiary's product cost increased due to natural disasters last year, leading to a decrease in gross profit margin, which continued to affect the current reporting period.